NCI Cancer News

Syndicate content National Cancer Institute
The latest cancer news from the U.S. government's principal agency for cancer research.
Updated: 13 min 25 sec ago

Norman Sharpless sworn in as director of the National Cancer Institute

16 hours 3 min ago

Norman E. “Ned” Sharpless, M.D., becomes the 15th director of the National Cancer Institute (NCI). He comes to NCI from the University of North Carolina School of Medicine, where he was director of the Lineberger Comprehensive Cancer Center.

Categories: NCI News

NCI-funded TMIST study compares 2-D and 3-D mammography for finding breast cancers

Mon, 09/25/2017 - 23:00

TMIST, the first randomized trial comparing two types of digital mammography for breast cancer screening, is enrolling participants. Developed by ECOG-ACRIN and NCI, the trial is comparing 2-D and 3-D mammography for finding breast cancers.

Categories: NCI News

NCI’s Douglas R. Lowy and John T. Schiller to receive 2017 Lasker Award

Tue, 09/05/2017 - 23:00

Dr. Douglas R. Lowy and Dr. John T. Schiller of the National Cancer Institute receive the 2017 Lasker-DeBakey Clinical Medical Research Award for their significant research leading to the development of HPV vaccines.

Categories: NCI News

NCI study identifies essential genes for cancer immunotherapy

Sun, 08/06/2017 - 23:00

A new NCI study identifies genes in cancer cells that are necessary for them to be killed by T cells, and therefore could be partially responsible for why immunotherapy doesn’t work in some patients.

Categories: NCI News

NCI study shows feasibility of cancer screening protocol for patients with Li-Fraumeni syndrome

Wed, 08/02/2017 - 23:00

A new NCI study demonstrates the feasibility of a comprehensive screening protocol for patients with Li-Fraumeni syndrome, a rare inherited disorder that leads to a higher risk of developing certain cancers.

Categories: NCI News

NCI-COG Pediatric MATCH trial to test targeted drugs in childhood cancers

Sun, 07/23/2017 - 23:00

The nationwide precision medicine trial will enroll children and adolescents with advanced cancers that haven’t responded to standard therapy to explore treatments targeted at specific genetic mutations.

Categories: NCI News